Case Study: Applying Scientific Expertise to Optimize Complex Safety-Focused DDI Studies
Drug-drug interactions (DDIs) can pose significant safety risks, particularly in cardiovascular therapies, where patients are often on multiple medications. By analyzing these interactions early, we can help your studies stay on track and avoid potential regulatory roadblocks.
Assessments for the 𝘐𝘯 𝘝𝘪𝘷𝘰 Tolerability and Efficacy of a JAK1-siRNA Being Developed for the Highly Targeted, Infrequent, and Efficacious Treatment of Inflammatory Skin Diseases Using Various Application Techniques
Validation of a Flow Cytometric Method for Immune Cell Populations Analysis in Miniature Swine Whole Blood with 71-Hour Pre-Stain Stability
A Validation Study of the Effects of Milrinone and Clonidine
Toxicological Reference Data for 6- to 9-Month Male and Female Sinclair Nanopigs®
Comparative Analysis of Background Gastrointestinal Characteristics in Cambodian, Vietnamese, and Mauritian Cynomolgus Monkeys
Rapid and Reproducible TAb/NAb AAV Assays Across Serotypes and Species to Support Global Preclinical Programs
A Validated Hybridization LC-MS/MS Method for Quantitative Bioanalysis of HT-KIT, a Vivo-Morpholino Antisense Oligonucleotide